<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:department>Experimental Medicine</gtr:department><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/FE4218ED-F3BA-43DB-8CFF-6CCB739FB454"><gtr:id>FE4218ED-F3BA-43DB-8CFF-6CCB739FB454</gtr:id><gtr:firstName>Julie</gtr:firstName><gtr:surname>Glanville</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0701335"><gtr:id>E29A4E6E-5BC1-46ED-ACCB-2C325B73EEF5</gtr:id><gtr:title>Functional Properties of Cytotoxic T Cells that Suppress HIV: The Good And The Bad</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0701335</gtr:grantReference><gtr:abstractText>An individual with Human Immunodeficiency Virus (HIV) attacks the infection with specialised white blood cells called cytotoxic T lymphocytes (CTL). Despite making large numbers of CTL, HIV infection cannot be cured or even prevented from progressing to AIDS. However, some individuals remain well for ten years after infection, and others succumb after a few months. We propose that this variable progression time between individuals is because some cytotoxic T cells are more effective at suppressing virus than others. Defining the characterisitcs of exactly what makes a CTL effective is very important to design an HIV vaccine that works. We aim to do this by studying CTL from volunteers with HIV, immortalised into clones. We will then compare how effectively each CTL clone suppresses HIV replication in infected cells in the laboratory. By identifying the most effective CTL clones and comparing them with less effective CTL clones, we can define those characteristics associated with good HIV suppression. One method we will use analyses the expression of thousands of genes simultaneously. This may identify a unique fingerprint for Good CTL, that can open new areas of research into the proteins that Good CTL express and may even identify new anti-viral factors, or drug targets.</gtr:abstractText><gtr:technicalSummary>Despite a cytotoxic T lymphocyte (CTL) response of high magnitude and breadth that is sustained through persistent infection, HIV infection progresses relentlessly to AIDS. It is becoming apparent in Non-Human primate models of SIV infection that not all CTL have the same capability to kill virally infected cells in vitro. We will focus on T cell quality in an effort to identify mechanisms that explain the failure of CTL to control HIV infection, with the specific aim of determining how CTL that are effective suppress HIV infection. This laboratory is in a unique position to undertake this research with an extensive panel of 29 T cell clones.

Objectives, Design and Methods: 
This project will determine the functional ability of each T cell clone directly by in vitro viral suppression assays (VSA). Once effective clones have been identified, the T cell quality can be defined even to the level of protein expression by using direct comparison with T cell clones with poor viral suppression but with similar functional avidity, or epitope specificity or T cell receptor.

1. Identify T cell clones with effective viral suppression in VSA and determine the functional avidity for each CTL by both Chromium release assay and IFN gamma ELISPOT. 
 
2. Characterisation of how CTL suppress virus first by cellular immune assays, using modified VSA to determine contribution of Killing versus cytokines. Cytokine profile in the supernatant will be analysed by luminex bead assay for 26 cytokines. Then CTL viral suppression will be examined at the level of gene expression using microarrays to compare mRNA between CTL able to suppress virus from CTL with poor in vitro suppression in both resting and stimulated cells. By comparing two groups of T cell clones we can internally control for unrelated factors. 

3. Leads derived from the microarray analysis will be developed using proteomics to define at the protein level how CTL suppress HIV.

Medical and Scientific Value
It is essential to define how CTL suppress HIV in order to design an effective HIV vaccine, which remains a high medical priority. Microarray analysis may define a unique mRNA profile of effective CTL valuable for prognosis or monitoring vaccine trials. We may even identify new anti viral factors. This will also further our understanding at the molecular level of how post receptor signaling and gene expression alter the efficacy of cellular immunity.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>222214</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Travelling Fellowship/British Society of Haematology</gtr:description><gtr:end>2008-12-02</gtr:end><gtr:fundingOrg>British Society for Haematology (BSH)</gtr:fundingOrg><gtr:id>2437EB42-A7FA-416B-814E-D39048C4306E</gtr:id><gtr:outcomeId>avczfAh9qrx0</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2008-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Reagent for study of HLA B*1302 specific CD8 T cell responses</gtr:description><gtr:id>B44712CB-9619-4ECC-966D-AC07B233FBAF</gtr:id><gtr:impact>In progress</gtr:impact><gtr:outcomeId>W4Gy7KtRaZZ</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>HLA B*1302 Tetramer</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>E6A69C01-C8CD-4D53-9649-C904175D5587</gtr:id><gtr:title>Frequency of red cell antibody alloimmunization in patients with sickle cell disease at Muhimbili National Hospital, Dar-es-Salaam, Tanzania</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2aee384770a26f345d796abf8672c5eb"><gtr:id>2aee384770a26f345d796abf8672c5eb</gtr:id><gtr:otherNames>Meda E.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>gm1Awp5XhaF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0F3DEEF4-C4B8-4D50-8CCD-26818D376153</gtr:id><gtr:title>The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/30373c619109bc39028647979ba3b159"><gtr:id>30373c619109bc39028647979ba3b159</gtr:id><gtr:otherNames>Mortensen M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>qNxVZGwy94P</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7F9EA2A2-2245-457C-979C-C06F7A194662</gtr:id><gtr:title>Antigen-sensitive CD8 T-cell clones with tough HIV-1 Suppression</gtr:title><gtr:parentPublicationTitle>The Lancet</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4657550dfd4fbb58bcfe597999177f53"><gtr:id>4657550dfd4fbb58bcfe597999177f53</gtr:id><gtr:otherNames>Glanville, Julie M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>Pi5zsvka6f1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>211EB91D-B44A-47B3-B737-C9548E0BADD3</gtr:id><gtr:title>Haematology in Tanzania</gtr:title><gtr:parentPublicationTitle>The Royal Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/423eed552497daf9ff8ae6e3d18301a2"><gtr:id>423eed552497daf9ff8ae6e3d18301a2</gtr:id><gtr:otherNames>David J Roberts</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:outcomeId>bqVrCC8acyv</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>92B8D070-C9F6-45F4-ABD0-42C9E67085DF</gtr:id><gtr:title>Ready for Action: HIV-1 suppression requires regulation beyond the TCR</gtr:title><gtr:parentPublicationTitle>Poster Presentation 139: Keystone Symposia, Protection from HIV-1: Targeted Intervention Strategies</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72509301c4cc3fb75e7577edef2441ba"><gtr:id>72509301c4cc3fb75e7577edef2441ba</gtr:id><gtr:otherNames>Glanville J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:outcomeId>WxKYnfZVyLt</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5833404-0BCC-4398-8D4C-86C98BFD039B</gtr:id><gtr:title>Prevalence and acquired causes of anaemia in children admitted to Muhimbili National Hospital (MNH), Dar es Salaam, Tanzania</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85b93ac9e6c5bf19fd2a0e76ea68ef7f"><gtr:id>85b93ac9e6c5bf19fd2a0e76ea68ef7f</gtr:id><gtr:otherNames>Magesa A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>fftsjGfRucM</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6E6AE03E-3833-4208-A120-CB67055205FC</gtr:id><gtr:title>Genome gains at chromosome 21q21/22 segment leads to co-amplification of Down Syndrome Critical Regions and known oncogenes in a case of donor cell-derived acute myeloid leukaemia following allogeneic sex mismatched umbilical cord blood transplantation for chronic myeloid leukaemia.</gtr:title><gtr:parentPublicationTitle>British journal of haematology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d1f6ddc0251b7658c43e5dc7f4ffe6a7"><gtr:id>d1f6ddc0251b7658c43e5dc7f4ffe6a7</gtr:id><gtr:otherNames>Castleton AZ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>r9Vss6ffej6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DAD51398-8F17-4030-AF42-3F0304DA4928</gtr:id><gtr:title>The burden and determinants of anaemia in HIV infected children attending public hospitals in Dar es Salaam</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/de3d26d14ac8f50d93b20754fa2f788a"><gtr:id>de3d26d14ac8f50d93b20754fa2f788a</gtr:id><gtr:otherNames>Makubi A.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>LsrGARDqDAT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>72E29EAE-B3BD-49FF-BD8A-4FB74B538F45</gtr:id><gtr:title>HLA B*08 FLK T Clones from Chronic HIV-1 infection have the same TCR and different polyfunctional Profiles</gtr:title><gtr:parentPublicationTitle>Keystone Symposia Abstract Book</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72509301c4cc3fb75e7577edef2441ba"><gtr:id>72509301c4cc3fb75e7577edef2441ba</gtr:id><gtr:otherNames>Glanville J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:outcomeId>rC36Dwspux1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BF641A99-CD4B-42A3-90E3-A94733B2DE68</gtr:id><gtr:title>De-escalation of the alemtuzumab dose prior to nonmyeloablative HLA-identical sibling transplantation: Crucial role of timing.</gtr:title><gtr:parentPublicationTitle>BLOOD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0b0b1f8b21dae23a775f8e7bf1bd6bb9"><gtr:id>0b0b1f8b21dae23a775f8e7bf1bd6bb9</gtr:id><gtr:otherNames>Chakraverty Ronjon</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>SPPqFNTtEoq</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8DF52D4A-AAE9-43BF-8939-0FF17CFD3BEA</gtr:id><gtr:title>MRI evidence of cardiac accumulation in myelodysplasia and unusual anaemias.</gtr:title><gtr:parentPublicationTitle>BLOOD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/04f1bb7a324b67064caa6aae2cdc7151"><gtr:id>04f1bb7a324b67064caa6aae2cdc7151</gtr:id><gtr:otherNames>Glanville Julie</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2006-01-01</gtr:date><gtr:issn>0006-4971</gtr:issn><gtr:outcomeId>CGtCL7Ntiet</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBF1BF56-2B65-4B82-A76E-623101F6F4FB</gtr:id><gtr:title>Neonatal screening for haemoglobinopathies at Muhimbili National Hospital, Dar es Salaam. A pilot study</gtr:title><gtr:parentPublicationTitle>BRITISH JOURNAL OF HAEMATOLOGY</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2541bb031d57a21bb62aa3356a20797"><gtr:id>b2541bb031d57a21bb62aa3356a20797</gtr:id><gtr:otherNames>Rwezaula S.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0007-1048</gtr:issn><gtr:outcomeId>d1LEY7XdKDa</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0701335</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>